The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro? | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro?

Acta Haematol (2005) 114 (4): 206–213.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy

Somnath Mukherjee
Opal Reddy
Sandhya Panch
David Stroncek

Transfusion and Apheresis Science (2021) 60 (1): 103066.

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study

Sara Galimberti
Elena Ciabatti
Giacomo Ercolano
Susanna Grassi
Francesca Guerrini
Nadia Cecconi
Martina Rousseau
Giulia Cervetti
Francesco Mazziotta
Lorenzo Iovino
Franca Falzetti
Flavio Falcinelli
Alberto Bosi
Luigi Rigacci
Sofia Kovalchuk
Daniele Vallisa
Lucia Macchia
Eugenio Ciancia
Mario Petrini

Frontiers in Pharmacology (2017) 8

Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice

Eric Bartee
Mee Y Bartee
Bjarne Bogen
Xue-Zhong Yu

Molecular Therapy - Oncolytics (2016) 3

Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission

Norbert-Claude Gorin
Myriam Labopin
Didier Blaise
Josy Reiffers
Giovanna Meloni
Mauricette Michallet
Theo de Witte
Michel Attal
Bernard Rio
Francois Witz
Loic Fouillard
Roel Willemze
Vanderson Rocha

Journal of Clinical Oncology (2009) 27 (24): 3987.